期刊文献+

三阴性乳腺癌中TOPOⅡα表达以及预后关系研究 被引量:1

Expression and Prognostic Significance of TopoⅡα in Triple Negative Breast Cancer
下载PDF
导出
摘要 目的探讨拓扑异构酶Ⅱα(topoisomeraseⅡα,TopoⅡα)表达与三阴性乳腺癌发生发展及预后的关系。方法应用SABC免疫组化法,检测186例三阴性乳腺癌(包括165例浸润性导管癌和21例导管原位癌)中TopoⅡα蛋白的表达水平。结果 TopoⅡα在浸润性导管癌组织以及导管原位癌组织中阳性表达率分别为73.9%和47.6%,TopoⅡα在有淋巴结转移者中阳性表达率高达80.9%,显著高于无淋巴结转移者(49.6%),两者相比差异具有统计学意义。TopoⅡα表达与患者年龄、肿瘤大小和临床分期以及组织学分级无关。结论 TopoⅡα的表达在三阴性乳腺癌的发生发展中扮演着重要的促进角色,也与有无淋巴结转移息息相关。 Objective To study the relationship between the expression of topoisomerase II alpha(topoisomerase II alpha,TopoⅡα) and the occurrence,development and prognosis of triple negative breast cancer. Methods the expression level of TopoⅡα protein was detected by SABC immunohistochemistry in 186 cases of triple negative breast cancer,including 165 cases of invasive ductal carcinoma and 21 cases of carcinoma in situ. Results the positive rate of TopoⅡαexpression in invasive ductal carcinoma tissues and the original parts were as follows:73. 9% and 47. 6%,Topo Ⅱα in patients with lymph node metastasis positive rate was 80. 9%,which was significantly higher than that without lymph node metastasis,49. 6%,the difference was statistically significant. The expression of TopoⅡα was not related to age,tumor size,stage and histological grade. Conclusion The expression of TopoⅡα plays an important role in the occurrence and development of triple negative breast cancer,and it is closely related to the existance of is lymph node metastasis.
作者 徐国萍 王杰 杨莉 何奇 XU Guoping;WANG Jie;YANG Li;et al(International Peace Maternal and Child Health Hospital,Shanghai Jiaotong University School of Medicine,Shanghai,20003)
出处 《实用癌症杂志》 2018年第5期724-727,共4页 The Practical Journal of Cancer
关键词 三阴性乳腺癌 TopoⅡα 免疫组化 Triple negative breast cancer Topo Ⅱα Immunohistochemistry
  • 相关文献

参考文献7

二级参考文献73

  • 1徐光辉,叶胜龙,郑义同,张为民,吉亚君.人乳腺癌中3种耐药基因产物的表达及其与预后的相关性[J].复旦学报(医学版),2005,32(1):33-35. 被引量:13
  • 2左文述,魏玲,宋现让,王兴武,王明玉,王永胜,于志勇,毕晔.浸润性乳腺癌组织中P-糖蛋白以及肺耐药蛋白和多药耐药相关蛋白表达的临床意义[J].中华医学杂志,2006,86(44):3142-3145. 被引量:9
  • 3Simpson P T,Reis-Filho J S,Gale T,et al.Molecular evolution of breast cancer[J].J Pathol,2005,205:248-54.
  • 4Sorlie T,Perou C M,Tibshirani R,et al.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications[J].Proc Natl Acad Sci USA,2001,98:10869-74.
  • 5Nielsen T O,Hsu F D,Jensen K,et al.Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J].Clin Cancer Res,2004,10:5367-74.
  • 6Dressler L,Berry D,Broadwater G,et al.Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients[J].J Clin Oncol,2005,23(19):4287-97.
  • 7O'Malley F P,Chai S,Tu D,et al.Topoisomerase Ⅱ alpha and responsiveness of breast cancer to adjuvant chemotherapy[J].J Natl Cancer Inst,2009,101(9):644-50.
  • 8Tang P,SKinner K A,Hicks D G,et al.Molecular classification of breast carcinomas by immunohistochemical analysis:Are we ready[J] ?Diagn Mol Pathol,2009,18:125-32.
  • 9Nielsen K V,Ejlertsen B.The value of TOP2A gene copy number variation as a biomarker in breast cancer:Update of DBCG trial 89D[J].Acta Oncol,2008,47:725-34.
  • 10龚西騟,丁华野.乳腺病理学[M].北京:人民卫生出版社,2009:325-8.

共引文献28

同被引文献9

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部